On August 29, 2023, representatives of JSC National Holding QazBioPharm held a meeting with representatives of Sinovac in the People’s Republic of China. During the meeting, Igor Mozolevich, Director of International Business Development (European Region), presented a company overview. Following the discussion, the parties agreed to explore the possibility of localizing the production of medicines from Sinovac’s portfolio at the Holding’s manufacturing facilities. The parties also agreed to sign a Non-Disclosure Agreement (NDA) to work out the details of the upcoming project. Arsen Meirembaev, Director of the Department of International Cooperation, Marketing and Promotion of the Holding, presented information about QazBioPharm’s activities and potential cooperation with Chinese manufacturers.

About Sinovac Biotech Ltd.: Sinovac Biotech Ltd. is a Chinese biopharmaceutical company engaged in the research, development, production, and sale of vaccines for the prevention of infectious diseases in humans. The company is headquartered in Beijing.

Commercial vaccines produced by Sinovac include Healive (against hepatitis A), Bilive (combined hepatitis A and B), Anflu (influenza), Panflu (H5N1), and PANFLU.1 (H1N1). Sinovac is currently developing a universal pandemic influenza vaccine and a vaccine against Japanese encephalitis.

Sinovac is also developing vaccines against Enterovirus 71, universal pandemic influenza, Japanese encephalitis, and rabies in humans. Its subsidiary, Tangshan Yian, conducts field trials of its self-developed inactivated rabies vaccines for animals.

In mid-April 2020, China approved clinical trials for the COVID-19 vaccine developed by Sinovac. The vaccine, named CoronaVac, is an inactivated whole-virus vaccine against COVID-19.